Cargando…

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma

BACKGROUND AND OBJECTIVES: Novel immunotherapy-based combination treatments have drastically improved clinical outcomes for previously untreated patients with advanced/metastatic renal cell carcinoma (aRCC). This study aimed to assess the temporal trends in grade 3/4 adverse event (AE) rates and ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Geynisman, Daniel M., Burotto, Mauricio, Porta, Camillo, Suarez, Cristina, Bourlon, Maria T., Huo, Stephen, Del Tejo, Viviana, Du, Ella X., Yang, Xiaoran, Betts, Keith A., Choueiri, Toni K., McGregor, Bradley
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250488/ https://www.ncbi.nlm.nih.gov/pubmed/35696045 http://dx.doi.org/10.1007/s40261-022-01170-6

Ejemplares similares

Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma
por: McGregor, Bradley, et al.
Publicado: (2023)

Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial
por: George, Daniel J., et al.
Publicado: (2019)

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2022)

Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma
por: Tran, Benjamin Duy, et al.
Publicado: (2023)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
por: Bersanelli, Melissa, et al.
Publicado: (2018)

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
por: Albiges, Laurence, et al.
Publicado: (2020)

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
por: Li, SiNi, et al.
Publicado: (2021)

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up
por: Tomita, Yoshihiko, et al.
Publicado: (2019)

Long-term follow-up results of nivolumab plus cabozantinib versus sunitinib for advanced renal cell cancer: Checkmate 9ER trial
por: Tarigopula, Vivek
Publicado: (2022)

Quality‐adjusted survival with first‐line cabozantinib or sunitinib for advanced renal cell carcinoma in the CABOSUN randomized clinical trial (Alliance)
por: Chen, Ronald C., et al.
Publicado: (2020)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
por: Motzer, Robert J, et al.
Publicado: (2022)

Exposure–Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma
por: Bajaj, Gaurav, et al.
Publicado: (2017)

Cabozantinib/ipilimumab/nivolumab interaction: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021)

Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2022)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
por: Wang, Hao, et al.
Publicado: (2022)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Five‐year survival with nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
por: Uhara, Hisashi, et al.
Publicado: (2021)

A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT‐01
por: Sahai, Vaibhav, et al.
Publicado: (2022)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study
por: Yamazaki, Naoya, et al.
Publicado: (2017)

Long‐term follow up of nivolumab in previously untreated Japanese patients with advanced or recurrent malignant melanoma
por: Yamazaki, Naoya, et al.
Publicado: (2019)

Cabozantinib for the treatment of solid tumors: a systematic review
por: Maroto, Pablo, et al.
Publicado: (2022)

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma
por: Motzer, Robert J., et al.
Publicado: (2018)

Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
por: Jansen, Caroline S., et al.
Publicado: (2023)

Complete response of metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus cabozantinib
por: Hayashida, Michikata, et al.
Publicado: (2023)

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial
por: Motzer, Robert J, et al.
Publicado: (2021)

Cabozantinib combination therapy for the treatment of solid tumors: a systematic review
por: Castellano, Daniel, et al.
Publicado: (2022)

Cabozantinib plus Nivolumab Phase I Expansion Study in Patients with Metastatic Urothelial Carcinoma Refractory to Immune Checkpoint Inhibitor Therapy
por: Girardi, Daniel M., et al.
Publicado: (2022)

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
por: Yau, Thomas, et al.
Publicado: (2023)

A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results
por: Eisen, T, et al.
Publicado: (2015)

Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
por: Choueiri, Toni K., et al.
Publicado: (2018)

Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2021)

Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity
por: Ho, Won Jin, et al.
Publicado: (2021)

Translational randomized phase II trial of cabozantinib in combination with nivolumab in advanced, recurrent, or metastatic endometrial cancer
por: Lheureux, Stephanie, et al.
Publicado: (2022)

Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma
por: Mi, Haoyang, et al.
Publicado: (2022)

Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms
por: Grünwald, Viktor, et al.
Publicado: (2023)

Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study
por: Pal, Sumanta K., et al.
Publicado: (2021)

Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial
por: Porta, Camillo, et al.
Publicado: (2012)

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
por: Apolo, Andrea B., et al.
Publicado: (2020)

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence
por: Zhang, Shuming, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_g0hkip9sknvs9jjbm5pm1jq3eg